High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation. He Jia-Jia,Shang Lei,Yu Qun-Wei,Jiao Ning,Qiu Shuang,Zhu Wei-Xiong,Wu Dong-Feng,Tian Yun-Er,Zhang Qing World journal of gastrointestinal oncology BACKGROUND:Protein phosphatase 2 regulatory subunit B'' alpha () gene has been reported in other tumors, but the influence of gene expression on the occurrence, development, and prognosis of hepatocellular carcinoma (HCC) remains unclear. AIM:To investigate whether the gene could be used to predict tumor recurrence and survival of HCC patients after liver transplantation (LT). METHODS:Diseased liver tissues of HCC patients after LT were collected as well as their clinical data and follow-up information. The immunohistochemical method was used to detect the expression of protein in the tissues of 108 patients with primary liver cancer. The test was used to analyze the relationship between protein expression levels and the clinicopathological features of tumors. The Kaplan-Meier method was used to analyze overall postoperative survival. The COX proportional hazard model was used to analyze adverse prognostic factors. RESULTS:Immunohistochemistry showed that the protein was mainly expressed in the cytoplasm of HCC cells. Compared to corresponding peritumoral tissues, expression was higher in HCC tissues ( 0.001). Correlation analysis showed that high expression was correlated with preoperative serum alpha-fetoprotein (AFP) levels ( = 0.003), tumor-node-metastasis-t stage ( 0.001), and envelope invasion ( = 0.001). Univariate analysis showed that overall survival ( 0.001) and recurrence-free survival ( = 0.025) of patients with high PPP2R3A expression (≥ 4 points) were poor compared to those with low expression (< 4 points). The overall survival rates or recurrence-free survival rates at 1, 2, and 3 years with high expression were 73%, 38%, and 23% or 31%, 23%, and 23%, respectively. Multivariate analysis showed that high expression (hazard ratio = 2.900, 95% confidence interval: 1.411-5.960, = 0.004) was an independent survival risk factor of HCC patients after LT, and it was also an independent predictor of postoperative tumor recurrence. This study also showed in patients with AFP ≥ 400 ng/mL, the overall survival ( 0.001) and recurrence-free survival ( = 0.023) of those with high expression were significantly worse compared to those with low expression. When expression was low, the overall survival rate ( = 0.461) or recurrence-free survival rate ( = 0.072) after LT in patients with AFP < 400 ng/mL and ≥ 400 ng/mL was not significantly difference. The 1, 2, and 3 year survival rate of patients with low expression and AFP < 400 ng/mL were 98%, 80%, and 69%, respectively, while patients who met Hangzhou criteria had a post-transplant 1, 2, and 3 years overall survival rate of 89%, 66%, and 55%, respectively. CONCLUSION:High expression of PPP2R3A might be a potential marker for predicting poor prognosis of HCC after LT. Combined with serum AFP levels, might enhance the accuracy of predicting HCC outcome in patients after LT and supplement the efficacy of the Hangzhou criteria. 10.4251/wjgo.v13.i7.716

Novel necroptosis-related gene signature for predicting the prognosis of pancreatic adenocarcinoma. Aging Pancreatic adenocarcinoma (PAAD) is a deadly digestive system tumor with a poor prognosis. Recently, necroptosis has been considered as a type of inflammatory programmed cell death. However, the expression of necroptosis-related genes (NRGs) in PAAD and their associations with prognosis remain unclear. NRGs' prediction potential in PAAD samples from The TCGA and GEO datasets was investigated. The prediction model was constructed using Lasso regression. Co-expression analysis showed that gene expression was closely related to necroptosis. NRGs were shown to be somewhat overexpressed in high-risk people even when no other clinical symptoms were present, indicating that they may be utilized in a model to predict PAAD prognosis. GSEA showed immunological and tumor-related pathways in the high-risk group. Based on the findings, immune function and m6A genes differ significantly between the low-risk and high-risk groups. MET, AM25C, MROH9, MYEOV, FAM111B, Y6D, and PPP2R3A might be related to the oncology process for PAAD patients. Moreover, CASKIN2, TLE2, USP20, SPRN, ARSG, MIR106B, and MIR98 might be associated with low-risk patients with PAAD. NRGs and the relationship of the immune function, immune checkpoints, and m6A gene expression with NRGs in PAAD may be considered as potential therapeutic targets that should be further studied. 10.18632/aging.203846